ACOR News and Press, Acorda Therapeutics Inc. From 01/11/19

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...

INBRIJA™ (levodopa inhalation powder) approved December 21, 2018 – first and only FDA-approved inhaled levodopa for intermittent treatment of OFF episodes in people with Parkinson’s taking carbidopa/levodopa INBRIJA expected to be available in Q1 2019 AMPYRA&#x...

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...

Recently, Acorda Therapeutics ( ACOR ) announced that it had received FDA approval for its inhaled levadopa treatment for patients with Parkinson's disease ((PD)). The FDA approval of INBRIJA will definitely help add revenue for the company. It won't be blockbuster status type revenue, b...

It has been a tough year for Acorda Therapeutics ( ACOR ) with their ongoing litigation over 4 patents for the company's moneymaker AMPYRA drug for multiple sclerosis "MS". AMPYRA generated ~$153M in sales during Q3 , but with generics grabbing the lion's share of the market, we can expect ...

Adamas Pharmaceuticals, Inc. ( ADMS ) has had a volatile 2018 experiencing all-time highs and lows. I recently published an article on Adamas reviewing the results of the company's 3rd quarter earnings report and subsequent demolition of the share price. In that article, I categorized ADMS...

HENDERSON, NV / ACCESSWIRE / December 26, 2018 / The news isn't all gloom and doom, the biotech companies highlighted below have all released positive news recently. We are highlighting: Endonovo Therapeutics, Inc. (ENDV), Adial Pharmaceuticals, Inc. (NASDAQ: ADIL), Auris Medical Holding A...

MINDBODY (NASDAQ: MB ) +68%  on being acquired by Vista Equity Partners for $1.9B. More news on: Mindbody, Acorda Therapeutics, Inc., Stocks on the move, , Read more ...

The FDA approves Acorda Therapeutics' (NASDAQ: ACOR ) INBRIJA for intermittent treatment of OFF episodes in people with Parkinson’s disease treated with carbidopa/levodopa. More news on: Acorda Therapeutics, Inc., Healthcare stocks news, Read more ...

First and Only FDA-Approved Inhaled Levodopa for Intermittent Treatment of OFF Episodes in People with Parkinson’s Taking Carbidopa/Levodopa Expected to be Available by Prescription in First Quarter 2019 Based on Innovative ARCUS ® Technology Platform for Inhaled Drug ...